Novel Treatment Advances and Approaches in the Management of Advanced Non-Small Cell Lung Cancer (NSCLC): Expert Perspectives on the Evolving Role of Immunotherapy

A continuing medical education activity sponsored by NAMCP and AAMCN

This webinar series will provide critical updates on the advances in the management of NSCLC

These are archives of live webinars held between June 16, 2021 to June 18, 2021
If you participated in any of the live webinars, you are not eligible
to claim credit from the archive of that webinar.

By clicking on each of the titles, you will be able to participate in each part.
It is not required that you participate in both or in order.

These activities are valid from August 1, 2021 to August 1, 2023


This series is supported by an educational grant from
Merck


 
Audience: This activity is intended for healthcare professionals practicing in managed care environments.

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

Description:
Lung cancer is the second most common cancer in both men and women, according to the American Cancer Society. It accounts for about 15% of all new cancers, and during 2020, it was expected that there were about 222,500 new cases of lung cancer. Non small-cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancer cases. Lung cancer is by far the leading cause of cancer death among both men and women, and there were an estimated 155,870 deaths from lung cancer in 2020, accounting for around 29% of all cancer deaths. More people die of lung cancer than of colon, breast, and prostate cancers combined. Recent clinical data have demonstrated that NSCLC is a very heterogeneous disease. However, as more comprehensive information has been gathered regarding tumor characterization, treatment modalities for NSCLC have expanded to include agents with more specific targets. The use of histologic subtypes and molecular biomarker assessment in NSCLC has resulted in therapeutic paradigms that can be optimized for individual patients based on unique characteristics of their cancer. Fortunately for patients with metastatic NSCLC, immune checkpoint inhibitors have become available in recent years, with more coming soon, that have showed improved efficacy, safety and outcomes, especially in patients with high levels of PD-L1 expression.

As more immunotherapies are becoming available, the treatment paradigm has grown expansive, making it difficult for clinicians and managed care professionals to make the appropriate decisions based on recent clinical data and guidelines. In this program on NSCLC, medical directors, oncologists, and nurses will learn about the optimal use of current and emerging immunotherapy treatment options and new options that are just becoming available, ultimately helping patients achieve a greater quality of life and improved clinical and economic outcomes.


Novel Treatment Advances and Approaches in the Management of Advanced Non-Small Cell Lung Cancer (NSCLC): Expert Perspectives on the Evolving Role of Immunotherapy

  1. Analyze the rationale underlying the use of immune checkpoint inhibition-based strategies for the management of advanced NSCLC
  2. Evaluate key clinical data on the use of current and emerging checkpoint inhibitors in the first-line treatment of squamous or non-squamous advanced NSCLC
  3. Compare and contrast safety and efficacy profiles of current and emerging immunotherapies, both alone and in combination, in the management of advanced NSCLC
  4. Evaluate novel IO-associated progression patterns and strategies for their appropriate monitoring and treatment
  5. Assess strategies for anticipating, recognizing, and managing immune-related adverse events of immune checkpoint inhibitors in advanced NSCLC
       Physician, Nursing and CMCN credits valid to August 1, 2023

Comparative Effectiveness and Coordinated Care in Advanced Non-Small Cell Lung Cancer (NSCLC): Managed Care Considerations on Immune Checkpoint Inhibitors

  1. Identify key economic challenges surrounding management of patients with advanced NSCLC
  2. Discuss the managed care considerations of current and emerging immunotherapies by exploring where these agents fit into the current advanced NSCLC management paradigm
  3. Analyze strategies used by managed care organizations to facilitate high quality care for members with advanced NSCLC, and how recent immunotherapy updates will affect those strategies
  4. Apply methods to enable optimal cost management of immunotherapies to be realized by multiple advanced NSCLC stakeholders including managed care organizations
       Physician, Nursing and CMCN credits valid to August 1, 2023